Treatment of Keratoconus With Advanced CXL-II

Launched by UMEÅ UNIVERSITY · Jul 30, 2015

Keywords

ClinConnect Summary

The study is designed as a prospective, open label, randomized controlled trial involving patients aged 12 years or older of both genders with uni- or bilateral keratoconus planned for routine corneal crosslinking (CXL) at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study involves 25+25 eyes with keratoconus, which are randomized to receive either conventional pulsed crosslinking with a uniform, universal 8 mm treatment pattern of 5.4 J/cm2 (pCXL; n=25), or a modified treatment - individualized topography-based corneal crosslinking (KXL2;...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients planned for corneal crosslinking.
• • 2. Uni-or bilateral keratoconus diagnosis based on the Amsler-Krumeich grading and the "Total Deviation" keratoconus quantification value from the "Belin-Ambrosio enhanced ectasia" measurements of the Pentacam HR® Scheimpflug camera, and an altered red reflex and/or an irregular cornea seen as distortion of the keratometric mires.
• • 3. Progression of the keratoconus in the eye in question, documented with Scheimpflug photography using the Oculus Pentacam HR® Scheimpflug camera and/or repeated subjective refraction and keratometry.
• • 4. Minimum corneal thickness of 400 μm at the thinnest point after epithelial removal.
• • 5. ≥12 years of age
• • 6. No ocular abnormalities except keratoconus
• • 7. No previous ocular surgery
• • 8. No cognitive insufficiency interfering with the informed consent.
• Exclusion Criteria:
• • 1. Age under 12
• • 2. Any corneal abnormalities except keratoconus
• • 3. Previous ocular surgery
• • 4. Cognitive insufficiency